Company Encyclopedia
View More
name
ZMC
600216.SH
Zhejiang Medicine Co., Ltd. manufactures and sells life nutrition and medical products in China and internationally. The company products include synthetic vitamin E, natural vitamin E, ß-carotene, cantharidin, vancomycin hydrochloride, and teicoplanin. It also offers fat-soluble vitamins, retinoids, quinolone antibiotics, anti-resistance antibiotics, and other products, as well as animal nutrition products.
3.105 T
600216.SHMarket value -Rank by Market Cap -/-

Financial Score

25/12/2025 Update
B
PharmaceuticalsIndustry
Industry Ranking23/223
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreB
    • ROE11.63%B
    • Profit Margin13.89%B
    • Gross Margin36.75%C
  • Growth ScoreC
    • Revenue YoY-0.81%D
    • Net Profit YoY27.21%B
    • Total Assets YoY5.26%B
    • Net Assets YoY5.67%B
  • Cash ScoreC
    • Cash Flow Margin720.07%B
    • OCF YoY-0.81%D
  • Operating ScoreB
    • Turnover0.65B
  • Debt ScoreA
    • Gearing Ratio20.69%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    BAIYUNSHAN PH fully acquires ZMC distribution company for a consideration of 500 million RMB

    BAIYUNSHAN PH announced that its subsidiary Guangzhou Medicine is acquiring 100% equity of Zhejiang Medical Industry from independent third party Haizheng Pharmaceutical through a public listing method. The latter is a pharmaceutical distribution enterprise in Zhejiang Province, primarily engaged in the wholesale of various pharmaceutical products, with a cash consideration of 500 million RMB

    AASTOCKS·
    SH
    600216
    -0.07%
    SH
    600332
    +0.15%
    HK
    00874
    -0.76%
    AASTOCKS·
    SH
    600216
    -0.07%
    SH
    600332
    +0.15%
    HK
    00874
    -0.76%

    Zhejiang Medicine: State Investment High-Tech plans to reduce its holdings by no more than 1% of shares

    According to the Zhitong Finance APP, ZMC announced that Guotou High-Tech plans to reduce its holdings by no more than 9.6164 million shares, or no more than 1% of the company's total share capital, through centralized bidding trading within three months after the announcement date, starting from 15 trading days after the disclosure

    Zhitong·
    SH
    600216
    -0.07%
    Zhitong·
    SH
    600216
    -0.07%

    Zhejiang Medicine released its semi-annual performance, with a net profit attributable to the parent company of 673 million yuan, a year-on-year increase of 113.52%

    According to the Zhitong Finance APP, ZMC disclosed its semi-annual report for 2025, reporting revenue of 4.323 billion yuan, a year-on-year decrease of 1.87%; net profit attributable to the parent company of 673 million yuan, a year-on-year increase of 113.52%; net profit excluding non-recurring gains and losses of 665 million yuan, a year-on-year increase of 110.10%; basic earnings per share of 0.70 yuan

    Zhitong·
    SH
    600216
    -0.07%
    Zhitong·
    SH
    600216
    -0.07%

    Zhejiang Medicine: Completed the repurchase of 1.43% of shares

    Zhejiang Medicine announced that on August 11, 2025, the company completed its share repurchase, accumulating a total of 13.7232 million shares through the centralized bidding method via the Shanghai Stock Exchange system, accounting for 1.43% of the company's current total share capital. The highest repurchase price was RMB 16.09 per share, the lowest price was RMB 13.31 per share, and the average repurchase price was RMB 14.57 per share, with a total amount of funds used being RMB 200 million. The repurchased shares will be used for the subsequent implementation of the employee stock ownership plan or equity incentives

    Zhitong·
    SH
    600216
    -0.07%
    Zhitong·
    SH
    600216
    -0.07%

    Zhejiang Medicine's subsidiary, Xinchang Pharmaceutical Factory, passed the on-site inspection by the U.S. FDA

    Zhejiang Medicine's subsidiary, Xinchang Pharmaceutical Factory, underwent a CGMP on-site inspection by the U.S. FDA from March 4 to March 7, 2025, covering four major systems including the quality system for oral solid preparations and active pharmaceutical ingredients. Xinchang Pharmaceutical successfully passed the inspection, meeting the U.S. drug CGMP quality system requirements, and has received the FDA's on-site inspection report confirming the completion of the inspection

    Zhitong·
    SH
    600216
    -0.07%
    Zhitong·
    SH
    600216
    -0.07%
    © 2025 Longbridge｜Disclaimer